| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e6f10141ac5f791e5b04c0489b69a95e |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-426
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4545
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-496
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4439
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-506
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5377 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-426
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-506
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5377
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4545
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-496
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4439 |
| filingDate |
2004-04-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_be0cfaab84686f2e24db6eb6c4573b13
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0e7dba1fa34337765d76c11b3d9f44e7 |
| publicationDate |
2004-11-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CA-2523852-A1 |
| titleOfInvention |
Use of tyrosine kinase inhibitors for treating cerebral ischemia |
| abstract |
The present invention relates to a method for treating cerebral ischemia, comprising administering a compound capable of depleting mast cells or a compound inhibiting mast cells degranulation to a human in need of such treatment. Such compounds can be chosen from tyrosine kinase inhibitors and more particularly non-toxic, selective and potent c-kit inhibitors. Preferably, said inhibitor is unable to promote death of IL-3 dependent cells cultured in presence of IL-3. Preferred compounds are 2-(3-amino)arylamino-4-aryl-thiazoles or 4-(4-methylpiperazine-l-ylmethyl)-N-[4-methyl-3-(4-pyridine-3-yl)pyrimidine-2~ylamino)phenyl]benzamide(imatinib). |
| priorityDate |
2003-04-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |